Perseus Proteomics Inc.

Tokyo Stock Exchange 4882.T

Perseus Proteomics Inc. EBT Margin for the year ending March 31, 2024: -1,098.12%

Perseus Proteomics Inc. EBT Margin is -1,098.12% for the year ending March 31, 2024, a -31.76% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.
  • Perseus Proteomics Inc. EBT Margin for the year ending March 31, 2023 was -833.40%, a -0.40% change year over year.
  • Perseus Proteomics Inc. EBT Margin for the year ending March 31, 2022 was -830.08%, a -37.13% change year over year.
  • Perseus Proteomics Inc. EBT Margin for the year ending March 31, 2021 was -605.31%, a 38.75% change year over year.
  • Perseus Proteomics Inc. EBT Margin for the year ending March 31, 2020 was -988.24%.
Key data
Date EBT Margin Net Income Margin EBITDA Margin EBIT Margin
Market news
Tokyo Stock Exchange: 4882.T

Perseus Proteomics Inc.

CEO Mr. Takuya Yokokawa
IPO Date June 22, 2021
Location Japan
Headquarters 30-1 Nihonbashi Hakozakicho
Employees 25
Sector Health Care
Industries
Biotechnology Pharmaceuticals
Description

Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.

StockViz Staff

January 15, 2025

Any question? Send us an email